Beta Bionics Files S-1/A for IPO

Ticker: BBNX · Form: S-1/A · Filed: Jan 22, 2025 · CIK: 1674632

Beta Bionics, Inc. S-1/A Filing Summary
FieldDetail
CompanyBeta Bionics, Inc. (BBNX)
Form TypeS-1/A
Filed DateJan 22, 2025
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$14.00, $16.00, $17.0 million, $15.00, $3.1 million
Sentimentneutral

Sentiment: neutral

Topics: ipo, sec-filing, medical-devices

TL;DR

Beta Bionics IPO filing updated. Looks like they're serious about going public.

AI Summary

Beta Bionics, Inc. filed an S-1/A amendment on January 22, 2025, for its initial public offering. The company, incorporated in Delaware, is based in Irvine, California, and operates in the surgical and medical instruments sector. The filing details its principal executive offices and agent for service, with Cooley LLP listed as counsel.

Why It Matters

This S-1/A filing indicates Beta Bionics is moving forward with its public offering, which could provide significant capital for its operations and growth in the medical device sector.

Risk Assessment

Risk Level: medium — As an S-1/A filing, it represents a company seeking to raise capital through an IPO, which inherently carries market and execution risks.

Key Numbers

  • 38 — Public Documents (Indicates the volume of documentation associated with this filing.)
  • 333-284147 — SEC File Number (Unique identifier for the SEC registration.)

Key Players & Entities

  • Beta Bionics, Inc. (company) — Registrant
  • January 22, 2025 (date) — Filing date
  • 333-284147 (registration_number) — SEC registration number
  • 11 Hughes Irvine, California 92618 (address) — Principal executive offices
  • Sean Saint (person) — President and Chief Executive Officer
  • Carlos Ramirez (person) — Counsel
  • Mark Weeks (person) — Counsel
  • Charles S. Kim (person) — Counsel
  • Cooley LLP (company) — Legal counsel

FAQ

What is the primary purpose of this S-1/A filing?

The primary purpose is to amend a previously filed registration statement (Form S-1) in preparation for an initial public offering (IPO).

When was this amendment filed with the SEC?

This amendment was filed as of January 22, 2025.

What is Beta Bionics, Inc.'s principal business address?

Beta Bionics, Inc.'s principal executive offices are located at 11 Hughes, Irvine, California 92618.

Who is listed as the President and Chief Executive Officer of Beta Bionics, Inc.?

Sean Saint is listed as the President and Chief Executive Officer of Beta Bionics, Inc.

Which law firm is representing Beta Bionics, Inc. in this filing?

Cooley LLP, with specific contacts Carlos Ramirez, Mark Weeks, and Charles S. Kim, is representing Beta Bionics, Inc.

Filing Stats: 4,549 words · 18 min read · ~15 pages · Grade level 15.3 · Accepted 2025-01-22 06:10:16

Key Financial Figures

  • $14.00 — rice for our common stock to be between $14.00 and $16.00 per share. We have applied t
  • $16.00 — r common stock to be between $14.00 and $16.00 per share. We have applied to list our
  • $17.0 million — nd we have agreed to sell approximately $17.0 million in shares of our common stock (the Priv
  • $15.00 — ssumed initial public offering price of $15.00 per share, which is the midpoint of the
  • $3.1 million — quarterly revenue has grown over 5xfrom $3.1 million for the quarter ended September 30, 202
  • $16.7 million — the quarter ended September 30, 2023 to $16.7 million for the quarter ended September 30, 202
  • $10.0 million — only 2x during the same time periodfrom $10.0 million to $19.9 million, respectively. Our r
  • $19.9 m — e same time periodfrom $10.0 million to $19.9 million, respectively. Our revenue for
  • $44.7 m — ine months ended September 30, 2024 was $44.7 million, more than 3.5x that of our annua
  • $12.0 million — than 3.5x that of our annual revenue of $12.0 million for the year ended December 31, 2023. O
  • $3.6 million — ine months ended September 30, 2023 was $3.6 million. Our net losses were $25.3 million for
  • $25.3 million — 3 was $3.6 million. Our net losses were $25.3 million for the nine months ended September 30,
  • $36.6 million — ine months ended September 30, 2023 and $36.6 million for the nine months ended September 30,
  • $11.0 million — ust 2023, which contributed a change of $11.0 million in the fair value of warrant liabilitie
  • $229.7 million — reflected in the accumulated deficit of $229.7 million and $278.6 million, as of December 31,

Filing Documents

Risk Factors

Risk Factors 25 Special Note Regarding Forward-Looking Statements 96 Market, Industry and Other Data 98 Dividend Policy 99

Use of Proceeds

Use of Proceeds 100 Capitalization 102

Managements Discussion and Analysis of Financial Condition and Results

Managements Discussion and Analysis of Financial Condition and Results of Operations 109

Business

Business 140 Management 205 Executive and Director Compensation 215 Certain Relationships and Related Party Transactions 232 Principal and Selling Stockholders 238

Description of Capital Stock

Description of Capital Stock 242 Shares Eligible for Future Sale 249 Material U.S. Federal Income Tax Consequences to Non-U.S. Holders of Our Common Stock 252

Underwriting

Underwriting 256 Legal Matters 266 Experts 266 Where You Can Find More Information 266 Index to Financial Statements F-1 Neither we, the selling stockholders nor the underwriters have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. Neither we, the selling stockholders nor the underwriters take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We, the selling stockholders and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date on the front cover of this prospectus, or other earlier date stated in this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: neither we, the selling stockholders nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. i Table of Contents PROSPECTUS SUMMARY This summary highlights selected information included elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in o

View Full Filing

View this S-1/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.